Advances in dendritic cell immunotherapies for HIV-1 infection

Expert Opinion on Biological Therapy

Volumn 14, Issue 11, 2014, Pages 1545-1549

  Miller, Elizabeth ^a   Bhardwaj, Nina ^b  

^a HESS CORPORATION   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cell; Human immunodeficiency virus; Immunotherapy; Therapeutic vaccine

Indexed keywords

CELL ANTIGEN; DENDRITIC CELL VACCINE; RNA; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CLINICAL EVALUATION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION; VIRUS INACTIVATION; VIRUS INHIBITION; ANIMAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; TRANSPLANTATION; TRENDS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY;

EID: 84911014389     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.950652     Document Type: Review

References (25)

1. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013;254:170-89
2. Miller EA, Spadaccia MR, O'Brien MP, et al. Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr 2012;61:535-44
3. Sapp M, Engelmayer J, Larsson M, et al. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Lett 1999;66:121-8
4. Buisson S, Benlahrech A, Gazzard B, et al. Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis 2009;199:1862-71
5. Smed-Sorensen A, Lore K, Walther-Jallow L, et al. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood 2004;104:2810-17
6. Vanham G, Van Gulck E. Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology 2012;9:72
7. Allard SD, De Keersmaecker B, de Goede AL, et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 2012;142:252-68
8. DeBenedette M, Tcherepanova I, Gamble A, et al. Immune function and viral load post AGS-004 administration to chronic HIV subjects undergoing STI. Conference on Retroviruses and Opportunistic Infections (CROI); 2014
9. Garcia F, Climent N, Assoumou L, et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011;203:473-8
10. Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013;5:166ra162
11. Gay C, Archin NM, Tcherepanova I, et al. Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. Conference on Retroviruses and Opportunistic Infections (CROI); 2014
12. Lu W, Arraes LC, Ferreira WT, et al. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-65
13. Macatangay BJ, Riddler SA, Wheeler ND, et al. Vaccination with autologous dendritic cells pulsed with autologous HIV-infected apoptotic cells. Conference on Retroviruses and Opportunistic Infections (CROI); 2014
14. Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010;134:140-7
15. Van Gulck E, Vlieghe E, Vekemans M, et al. mRNA-based dendritic cell vaccination induces potent antiviral Tcell responses in HIV-1-infected patients. Aids 2012;26:F1-F12
16. Lu W, Wu X, Lu Y, et al. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003;9:27-32
17. Rossio JL, Esser MT, Suryanarayana K, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998;72:7992-8001
18. Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol 2013;13:487-98
19. Hanke T. Conserved immunogens in prime-boost strategies for the nextgeneration HIV-1 vaccines. Expert Opin Biol Ther 2014;14:601-16
20. Lubong Sabado R, Kavanagh DG, Kaufmann DE, et al. In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One 2009;4:e4256
21. Boaz MJ, Waters A, Murad S, et al. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002;169:6376-85
22. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50
23. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9
24. Vingert B, Benati D, Lambotte O, et al. HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol 2012;86:10661-74
25. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211